Melanoma pathway targeted

摘要

A drug that targets the RAS signalling cascade - which is thought to drive tumour growth in 20% of cancers -improves survival in some patients with advanced melanoma.rnThe drug, called trametinib, inhibits MEK, a protein that amplifies cancer-promoting signals. Keith Flaherty at the Massachusetts General Hospital in Boston and his team tested trametinib in melanoma patients with a mutated version of a RAS-pathway protein BRAF, which is mutated in 50% of advanced melanoma patients.